planchs@ccf.org (US) harriet.howard5@nhs.net (UK) www.deliver-ms.com

September 2026

Does early treatment with highly effective DMT improve prognosis for people with MS?

Welcome to the DELIVER-MS newsletter

We would like to thank all the sites for their efforts on both DELIVER-MS and DELIVER-MS Long Term Extension (LTE). For DELIVER-LTE there are 23 sites that have enrolled at least one patient and 1 site pending activation. We have also started tracking patients who have already reached M48 and have not enrolled in the LTE. Please reach out if you have any questions about enrollment!



*2 patients from Cardiff have transferred to Bristol, 1 from Nottingham to Leeds, 1 from Rochester to Cleveland *

REMINDERS

-Please push EVERY visit to QA! Data can only be reviewed/analyzed by the central team when a visit is in QA

-Complete M36 MRIs on the DELIVER approved scanner is a must and should be done without exception in all DELIVER participants

-Please ensure that observational participants complete their M36 MRI within the insurance window using the DELIVER protocol

-MRIs in the LTE are flexible and preferred on DELIVER approved scanner if possible (will still accept MRIs if not on the DEL approved scanner)

-Let us know if a participant declines the LTE

-Please ensure that DEL LTE invoices are being sent for review and payment

🎉 Site Shoutout 🎉

We wanted to highlight a US and a UK site to learn a little more about what makes each site so special! Check out the end of the newsletter to find out more about

FINAL THOUGHTS

We want to thank you all for your ongoing dedication to DELIVER-MS and now the LTE. Please reach out to our team if you have any questions!

Relevant Links

Our website is:
www.deliver-ms.com

Our mailing address is:
planchs@ccf.org (US) and harriet.howard5@nhs.net (UK)

planchs@ccf.org (US) harriet.howard5@nhs.net (UK) www.deliver-ms.com

⭐ The University of Texas at Austin ⭐

Dr. Léorah Freeman, MD, PhD, is the PI of the DELIVER-MS site at The University of Texas at Austin, where she is also the director the Multiple Sclerosis and Neuroimmunology Center & MS Imaging & Outcomes Lab. Over two decades of clinical practice, she has cared for patients with multiple sclerosis and its rarer relatives — NMOSD, MOGAD, autoimmune encephalitis — and, increasingly, for patients with dysautonomia, hEDS and small fiber neuropathy. She earned her MD and PhD (in neurosciences) from Université Pierre et Marie Curie in Paris, where she also completed her neurology residency. She trained in MS and neuroimmunology through fellowships at La Pitié-Salpêtrière in Paris and UTHealth in Houston, TX. She now lives in Austin with her husband and five children. In her spare time, she loves to write – you can find her on Substack as *The Neuroimmunologist* where she writes about translating clinical research on MS & other neuroimmune conditions into practical guidance for patients, families, and clinicians.



The MS Imaging & Outcomes Lab is a small operation with a big impact -- we are currently a team of 3: Lauren (CRC, study coordinator for DELIVER-MS), Missy (senior research coordinator) & Kris (senior RN research coordinator). The lab's research centers on improving MS diagnosis, treatment, and care through innovative, collaborative work. Our research pursues diagnostic tools and therapies aimed at making a tangible difference in patients' lives, both now and in the future. Underlying all of this is a focus on understanding the full lived experience of MS, using a whole-person perspective to shape both current patient care and the broader future of the field.

Living in Austin has its own rhythm — breakfast tacos are basically a food group, you can find awesome live music any day of the week, and there's always a reason to be outside, whether it's kayaking on Lady Bird Lake or catching a sunset at Mount Bonnell (although the summers can be brutal...) The city has grown a lot in recent years, but still holds onto that laid-back, "Keep Austin Weird" charm. The picture included shows Bull Creek District Park, one of our favorite spots to get some fresh air!

planchs@ccf.org (US) harriet.howard5@nhs.net (UK) www.deliver-ms.com

⭐ Nottingham University Hospitals NHS Trust ⭐

Principal Investigator: Dr. Nikos Evangelou

Nottingham University Hospitals NHS Trust (NUH) is at the forefront of new surgical procedures and research programmes. NUH is home to the East Midlands Major Trauma Centre, the Nottingham Children's Hospital and in partnership with the University of Nottingham we host a Biomedical Research Centre carrying out vital research into hearing, digestive diseases, respiratory, musculoskeletal disease, mental health and imaging. We are proud of our strong relationships with universities across the East Midlands, including the University of Nottingham, Nottingham Trent University and Loughborough University. We have recently opened a brand-new 70-bed NHS rehabilitation facility on the Stanford Hall Rehabilitation Estate near Loughborough which aims to transform rehabilitation provision in England. Together, Nottingham's blend of history, innovation, and community spirit makes it a unique place to live, work, and conduct world leading research such as pioneering magnetic resonance imaging as a medical diagnostic tool.

The Deliver-MS team is delighted to contribute to this important study, supporting research that aims to improve treatment decisions and outcomes for people living with multiple sclerosis (MS). Our dedicated team works collaboratively with participants, clinicians, research practitioners, research nurses, MS nurses and administrative team to ensure high-quality data collection and excellent participant care throughout the study journey.

We are grateful to all our participants whose commitment makes this research possible and helps advance our understanding of MS treatment strategies for future patients. Of the 120 participants recruited into the main study, 64 are currently enrolled in the Long-Term Extension (LTE) study (Months 48 to 72). A further 10 participants have recently completed the main study and will soon be invited to join the LTE, while the remaining 7 participants continue their follow-up within the main study. Of the 64 participants already enrolled in the LTE, 33 have successfully completed Month 72 and are now being invited to participate in a further extension study covering Months 84 to 108.